Healthcare / Medical DevicesShanghai
$15.40
+0.09 (+0.59%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $39.1M · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.1B
P/E
90.6x
↑EV/EBITDA
50.9x
↑ROE
3.0%
↑Gross Margin
74.9%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.8%
FCF CAGR
+30.0%
FCF margin
7.2%
FCF / Net income
0.62x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $542.8M · net income $63.1M · FCF $39.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $542.8M | $542.8M | $453.6M | $460.4M | $649.2M |
| Net Income | $63.1M | $63.1M | $11.5M | $95.6M | $190.8M |
| EBITDA | $94.8M | $94.8M | $61.4M | $165.2M | $258.7M |
| EPS | 0.19 | 0.19 | 0.04 | 0.32 | 0.64 |
| Gross Margin | 74.9% | 74.9% | 71.3% | 80.0% | 90.2% |
| Operating Margin | 14.9% | 14.9% | 6.0% | 24.8% | 29.1% |
| Net Margin | 11.6% | 11.6% | 2.5% | 20.8% | 29.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.00 | 0.00 |
| Current Ratio | 5.85 | 5.85 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $39.1M | $39.1M | $-26.5M | $241.5M | $17.8M |
| Returns | |||||
| ROE | 3.0% | 3.0% | 0.6% | 5.0% | 10.4% |
| Valuation | |||||
| P/E | 90.59 | 90.59 | 402.29 | 46.74 | 33.25 |
| EV/EBITDA | 50.86 | 50.86 | 69.31 | 23.11 | 23.22 |
| P/B | 2.43 | 2.43 | 2.41 | 2.33 | 3.45 |
| Growth & Yield | |||||
| Revenue Growth | 19.7% | 19.7% | -1.5% | -29.1% | — |
| EPS Growth | 375.0% | 375.0% | -87.4% | -50.6% | — |
| Dividend Yield | 0.0% | 0.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
93.0%
EPS terminal req.
$1.37
Spread vs growth
282.0%
5Y implied EPS CAGR
54.1%
EPS terminal req.
$1.65
Spread vs growth
320.9%
10Y implied EPS CAGR
30.2%
EPS terminal req.
$2.66
Spread vs growth
344.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.5%
Start / end P/E
416.5x → 81.1x
EPS bridge
0.04 → 0.19
Residual
-302.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.